Eli Lilly disclosed plans to submit a regulatory application for retatrutide, its next-generation obesity treatment, during the first quarter of 2027. The company had previously indicated it might seek approval earlier in the year but determined it needed additional time to compile and validate manufacturing and quality-control documentation required by regulatory authorities.
Two Phase 3 clinical trials demonstrated that retatrutide produced meaningful weight loss and favorable changes in blood sugar measures among adults with obesity who also had Type 2 diabetes or established cardiovascular disease. In one trial, participants with obesity and diabetes achieved average weight loss of 20.8% of body weight, approximately 50 pounds, over an 80-week period. A second trial involving adults with severe obesity and cardiovascular disease showed average weight loss of 22.6% of body weight, roughly 55.8 pounds, during the same timeframe. The drug also reduced certain cardiovascular risk factors in this population.
Retatrutide functions as a triple-action treatment, targeting GLP-1, GIP, and glucagon pathways simultaneously, which distinguishes it from existing weight loss medications that typically act on one or two of these hormonal mechanisms. This mechanism appears to produce more potent effects on appetite suppression and satiety compared to current alternatives. Adverse effects remained consistent across the two trials and earlier studies, with gastrointestinal symptoms such as diarrhea, nausea, and constipation reported most frequently—effects common to the broader GLP-1 drug class.
With positive results now from five late-stage trials, retatrutide represents the third major component of Lilly’s obesity medication portfolio, following its injection Zepbound and recently introduced oral medication Foundayo. Financial analysts have projected the drug could generate approximately $3.8 billion in annual sales by 2030, positioning it as a significant contributor to Lilly’s competitive standing against Novo Nordisk in the rapidly expanding weight loss and diabetes treatment market, projected to reach roughly $100 billion by the 2030s.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI